Advancing immunology,
transforming tomorrow's healthcare!

mib-marseille immunilogie biocluster
mib-marseille immunilogie biocluster

This Biocluster aims to establish Marseille as a world-class center for immunotherapy. Involving public and private players, MIB brings together experts in immunology (research, industry, healthcare, training, start-ups), with strong support from local authorities such as the Aix-Marseille-Provence Metropolis, the Bouches-du-Rhône Department and the Provence-Alpes-Côte-d’Azur Region.

About

Marseille Immunology Biocluster, a vision for the future

Marseille Immunology Biocluster (MIB) is a winning project in France’s national “Bioclusters” call for projects, with a government investment of €96 million.

mib-marseille immunilogie biocluster
mib-marseille immunilogie biocluster

€96 million

State investment

It brings together major players in research, healthcare, innovation and local authorities, and aims to accelerate the development of immunotherapy antibodies against serious diseases such as inflammatory and autoimmune diseases, cancers and infections.

mib-marseille immunilogie biocluster

Marseille Immunology Biocluster (MIB) is a winning project in France’s national “Bioclusters” call for projects, with a government investment of €96 million.

mib-marseille immunilogie biocluster

Newsletter

Receive quarterly news from the Marseille Immunology Biocluster.
Your e-mail address will only be used to send this newsletter, and you can unsubscribe at any time.
Find out more about how we manage your personal data

News

Latest news

Denis Bertin

Testimonials

“Bringing together clinicians, researchers and entrepreneurs to develop new drug candidates, MIB is set to transform the management of inflammatory, autoimmune and infectious diseases.”
Denis Bertin,
Vice-Chairman of the Amidex Foundation
France 2030 Coordinator
Denis Bertin
Marie Roumieux
Norbert Vey
Daniel Olive
previous arrow
next arrow
Denis Bertin
Testimonials
“Bringing together clinicians, researchers and entrepreneurs to develop new drug candidates, MIB is set to transform the management of inflammatory, autoimmune and infectious diseases.”
Denis Bertin,
Vice-Chairman of the Amidex Foundation
France 2030 Coordinator
Denis Bertin
Marie Roumieux
Norbert Vey
Daniel Olive
previous arrow
next arrow

Partners & founders

Founding organizations